On June 21, 2011, Ohr Pharmaceutical announced that they are advancing their clinical Wet Age-related Macular Degeneration program with a topical formulation. The anti-VEGF substance has been reformulated from an intravenous infusion to a topical eye drop. Phase one and two of this trial have shown a good safety and efficacy profile in both early and advanced Wet-AMD. “The Squalamine eye drop program has the potential to create a monumental shift in the way patients are treated for Wet-AMD,” commented Dr. Shalom Z Hirschman, Ohr’s Chief Scientific Advisor.
PRINT
